BOSTON SCIENTIFIC CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BSX in the last 30 days.
See all $BSX insider activity →Boston Scientific (BSX) reported Q3 revenue of $5.14B, beating estimates, but EPS missed. Shares fell 3.48% pre-market due to weak Q4 and full-year guidance. The company cited a cybersecurity incident as a challenge. Cardiovascular and MedSurg segments showed modest growth, with mixed international results.
Boston Scientific reported Q3 Non-GAAP EPS of $0.73, beating estimates by $0.01, with revenue of $5.14B, up 1.4% year-over-year. The company reduced its 2026 guidance, citing a cyberattack's impact on sales, with adjusted EPS forecasted at $3.16–$3.18, below the consensus of $3.23.
BOSTON SCIENTIFIC CORP (BSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Boston Scientific announces results for third quarter 2026 Marlborough, Mass. (October 28, 2026) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, operation
Over the past 7 days, AlphAI's AI scored 15 news stories mentioning BSX (BOSTON SCIENTIFIC CORP). Coverage has skewed bearish: 3 bullish, 3 neutral, and 9 bearish.
Recent BSX coverage spans financial news, earnings and market movers.
Guidance miss signals weaker near‑term earnings, likely pressuring the stock.
Guidance miss suggests earnings pressure.
Quarterly earnings miss and modest guidance may weigh on the stock.
New Costa Rica manufacturing capacity supports longer-term device supply and employment, but the article provides no direct financial guidance.
Analyst downgrade reflects expected revenue shortfall and earnings pressure.
AlphAI scores every news story that mentions BSX with an AI model for sentiment and relevance, and aggregates insider trades from BOSTON SCIENTIFIC CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Boston Scientific (BSX) reported Q3 revenue of $5.14B, beating estimates, but EPS missed. Shares fell 3.48% pre-market due to weak Q4 and full-year guidance. The company cited a cybersecurity incident as a challenge. Cardiovascular and MedSurg segments showed modest growth, with mixed international results.
2 min readBoston Scientific reported Q3 Non-GAAP EPS of $0.73, beating estimates by $0.01, with revenue of $5.14B, up 1.4% year-over-year. The company reduced its 2026 guidance, citing a cyberattack's impact on sales, with adjusted EPS forecasted at $3.16–$3.18, below the consensus of $3.23.
1 min readBOSTON SCIENTIFIC CORP (BSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Boston Scientific announces results for third quarter 2026 Marlborough, Mass. (October 28, 2026) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, operation
2 min readCosta Rica received $5.12B in foreign direct investment in 2025, with 54.8% from the U.S. Medical devices were the largest export. Key investors include Boston Scientific, Medtronic, Intel, and Bayer. The free-zone regime, offering tax incentives, attracted 66.4% of investments. The U.S. is the top trading and security partner, while China, the IMF, and the World Bank have narrower roles.
8 min readStifel reduced its price target for Boston Scientific (BSX) to $55 from $60, citing the impact of a cyberattack. The company expects material effects on Q3 2026 and full-year 2026 results, leading to lower revenue projections and revised earnings estimates. Analysts remain divided, with some maintaining buy ratings and others lowering targets due to competitive pressures.
2 min readAnalysts maintained Buy ratings on Relay Therapeutics (RLAY), Boston Scientific (BSX), and Palisade Bio (PALI). Price targets set at $25 for RLAY, $66 for BSX, and $7 for PALI. All three have Strong Buy consensus ratings.
2 min readOn October 21, 17 ETFs added shares of Boston Scientific (BSX) totaling $23.9 million, extending a three-day streak of net inflows. The largest buyers were CGGO, IHI, and SPYM. BSX operates in the medical devices sector with a market cap of $66.7 billion. ETFs have been net buyers of BSX in 3 of the last 5 days.
2 min readBoston Scientific Corp. shares rose 3.37% to $46.01 on Thursday, outperforming the broader market. The stock remains 56.45% below its 52-week high of $105.65. The Dow Jones Industrial Average gained 0.02%, while the S&P 500 fell 1.21%.
1 min readPenumbra, Inc. received FDA clearance for its Lightning device to treat deep vein thrombosis. Boston Scientific Corp. agreed to acquire Penumbra in a cash and stock deal. Penumbra's stock may be affected by the acquisition and new product approval.
1 min readBoston Scientific (BSX) stock has potential for growth outside its WATCHMAN and electrophysiology businesses, which management expects to keep growing. The company's operating margin improved to 22.9% in Q2 2026, but management anticipates challenges in 2027 due to softness in WATCHMAN and electrophysiology. BSX trades at 17.8 times its past year's earnings, cheaper than the S&P 500, but with limited expected EPS growth in 2027.
2 min read
